ECOG 1A05: Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade) –Lenalidomide (Revlimid) –Dexamethasone (VRD) versus Bortezomib (Velcade) –Dexamethasone (VD) for Patients With Multiple Myeloma who have completed a Dexamethasone Based Induction Regimen.
Phase of Trial: Phase III
Latest Information Update: 30 Jun 2015
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 25 Jun 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 01 Jul 2013 Planned end date changed from 1 Apr 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.
- 11 Jul 2012 Planned end date changed from 1 Aug 2009 to 1 Apr 2013 as reported by ClinicalTrials.gov.